Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance

The development of HIV integrase (IN) strand transfer inhibitors (INSTIs) and our understanding of viral resistance to these molecules have been hampered by a paucity of available structural data. We recently reported cocrystal structures of the prototype foamy virus (PFV) intasome with raltegravir and elvitegravir, establishing the general INSTI binding mode. We now present an expanded set of cocrystal structures containing PFV intasomes complexed with first- and second-generation INSTIs at resolutions of up to 2.5 Å. Importantly, the improved resolution allowed us to refine the complete coordination spheres of the catalytic metal cations within the INSTI-bound intasome active site. We show that like the Q148H/G140S and N155H HIV-1 IN variants, the analogous S217H and N224H PFV INs display reduced sensitivity to raltegravir in vitro. Crystal structures of the mutant PFV intasomes in INSTI-free and -bound forms revealed that the amino acid substitutions necessitate considerable conformational rearrangements within the IN active site to accommodate an INSTI, thus explaining their adverse effects on raltegravir antiviral activity. Furthermore, our structures predict physical proximity and an interaction between HIV-1 IN mutant residues His148 and Ser/Ala140, rationalizing the coevolution of Q148H and G140S/A mutations in drug-resistant viral strains.

[1]  R. Geleziunas,et al.  Preclinical Evaluation of GS-9160, a Novel Inhibitor of Human Immunodeficiency Virus Type 1 Integrase , 2008, Antimicrobial Agents and Chemotherapy.

[2]  A. Skalka,et al.  Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases , 1992, Molecular and cellular biology.

[3]  P. Roversi,et al.  Functional and structural characterization of the integrase from the prototype foamy virus , 2008, Nucleic acids research.

[4]  Robert Craigie,et al.  Retroviral DNA integration: reaction pathway and critical intermediates , 2006, The EMBO journal.

[5]  A. Engelman,et al.  Retroviral intasome assembly and inhibition of DNA strand transfer , 2010, Nature.

[6]  Satoru Ikeda,et al.  Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. , 2006, Journal of medicinal chemistry.

[7]  Yves Pommier,et al.  Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir. , 2010, Biochemistry.

[8]  Wei Yang,et al.  Crystal Structures of RNase H Bound to an RNA/DNA Hybrid: Substrate Specificity and Metal-Dependent Catalysis , 2005, Cell.

[9]  V. Soriano,et al.  Resistance to integrase inhibitors. , 2007, Journal of HIV therapy.

[10]  Randy J Read,et al.  Automated structure solution with the PHENIX suite. , 2008, Methods in molecular biology.

[11]  E. Garvey,et al.  Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. , 2008, Antiviral research.

[12]  Patrick L. Hindmarsh,et al.  Retroviral DNA Integration , 1984, Microbiology and Molecular Biology Reviews.

[13]  Wei Xu,et al.  A potent and orally active HIV-1 integrase inhibitor. , 2007, Bioorganic & medicinal chemistry letters.

[14]  K. Hertogs,et al.  Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors , 2008, Journal of Virology.

[15]  P. Cherepanov.  LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro , 2006, Nucleic acids research.

[16]  J A Grobler,et al.  Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. , 2000, Science.

[17]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[18]  Y. Pommier,et al.  Scaffold rearrangement of dihydroxypyrimidine inhibitors of HIV integrase: Docking model revisited. , 2010, Bioorganic & medicinal chemistry letters.

[19]  Krishan Kumar Pandey,et al.  Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors. , 2010, Biochemistry.

[20]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[21]  R. Paredes,et al.  Clinical management of HIV-1 resistance. , 2010, Antiviral research.

[22]  A. Voet,et al.  Mutations in Human Immunodeficiency Virus Type 1 Integrase Confer Resistance to the Naphthyridine L-870,810 and Cross-Resistance to the Clinical Trial Drug GS-9137 , 2008, Antimicrobial Agents and Chemotherapy.

[23]  C. Charpentier,et al.  Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy * , 2008, HIV medicine.

[24]  Dominique Schols,et al.  Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. , 2010, Virology.

[25]  Deenan Pillay,et al.  Update of the Drug Resistance Mutations in HIV-1: December 2008 , 2008 .

[26]  D. Hazuda,et al.  Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. , 2008, Journal of medicinal chemistry.

[27]  A. Engelman,et al.  Structure-based modeling of the functional HIV-1 intasome and its inhibition , 2010, Proceedings of the National Academy of Sciences.

[28]  Goedele N. Maertens,et al.  The mechanism of retroviral integration through X-ray structures of its key intermediates , 2010, Nature.

[29]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[30]  Jack Snoeyink,et al.  Nucleic Acids Research Advance Access published April 22, 2007 MolProbity: all-atom contacts and structure validation for proteins and nucleic acids , 2007 .

[31]  E. Dimitriadis,et al.  Nucleoprotein intermediates in HIV-1 DNA integration visualized by atomic force microscopy. , 2010, Journal of molecular biology.

[32]  A. Engelman,et al.  Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro , 1992, Journal of virology.

[33]  F. Bushman,et al.  Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition , 1997, Journal of virology.

[34]  Xiaowu Chen,et al.  Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. , 2010, Antiviral research.

[35]  Mary K. Lewinski,et al.  Retroviral DNA integration--mechanism and consequences. , 2005, Advances in genetics.

[36]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[37]  Yves Pommier,et al.  HIV-1 IN inhibitors: 2010 update and perspectives. , 2009, Current topics in medicinal chemistry.

[38]  Luba Tchertanov,et al.  The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation , 2008, Nucleic acids research.

[39]  W. Haseltine,et al.  Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex , 1991, Journal of virology.

[40]  G. Kleywegt,et al.  Detecting folding motifs and similarities in protein structures. , 1997, Methods in enzymology.

[41]  Hongtao Xu,et al.  Identification of Novel Mutations Responsible for Resistance to MK-2048, a Second-Generation HIV-1 Integrase Inhibitor , 2010, Journal of Virology.

[42]  D. Hazuda,et al.  Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. , 2008, The New England journal of medicine.